Karen Noblett - Sep 12, 2022 Form 4 Insider Report for Axonics, Inc. (AXNX)

Role
Chief Medical Officer
Signature
/s/ Dan Dearen, as Attorney-in-Fact for Karen Noblett
Stock symbol
AXNX
Transactions as of
Sep 12, 2022
Transactions value $
-$1,915,465
Form type
4
Date filed
9/20/2022, 08:23 PM
Previous filing
Sep 9, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXNX Common Stock Options Exercise $263K +18.5K +58.61% $14.19* 50.1K Sep 12, 2022 Direct
transaction AXNX Common Stock Options Exercise $361K +14K +27.86% $25.82 64.1K Sep 12, 2022 Direct
transaction AXNX Common Stock Sale -$2.54M -32.5K -50.69% $78.16 31.6K Sep 12, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXNX Stock Option (Right to Buy) Options Exercise $0 -18.5K -86.21% $0.00 2.96K Sep 12, 2022 Common Stock 18.5K $14.19 Direct F2
transaction AXNX Stock Options (Right to buy) Options Exercise $0 -14K -68.75% $0.00 6.35K Sep 12, 2022 Common Stock 14K $25.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $78.00 to $78.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.
F3 The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.